Member Exclusive

Epigenetic regulatory mechanism results in breast cancer drug resistance

A new finding from researchers at Memorial Sloan Kettering Cancer Center (New York, NY, USA) revealed that the PI3K pathway activates the ER pathway through an epigenetic mechanism using a protein called KMT2D. The discovery of this epigenetic link could guide future long-term therapeutic strategies.

Go to the profile of Peter Brown
Apr 03, 2017

Please sign in or register for FREE to view this content

Register to EpigenomicsNet – the epigenetics and epigenomics network

EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet. Start the conversation...